Published on December 25, 2024, in the Journal of Hematology & Oncology, this review explores the evolving role of immunotherapy in breast cancer treatment, highlighting key advancements in immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), cancer vaccines, and cellular therapies.
Checkpoint inhibitors: Pembrolizumab, combined with chemotherapy, is FDA-approved for PD-L1+ metastatic and early-stage triple-negative breast cancer (TNBC), with ongoing trials expanding its use to hormone receptor-positive and HER2-positive disease.
Antibody-drug conjugates (ADCs): Already approved for TNBC and HER2+ breast cancer, ADCs are under investigation in combination with ICIs for greater efficacy.
Cancer vaccines: Targeting HER2, Muc-1, and CEA, these vaccines aim to stimulate long-term immune responses with minimal side effects.
Cellular therapies: Approaches like CAR-T cells, tumor-infiltrating lymphocytes, and TCR-engineered cells show potential for more targeted immunotherapy.
Thanks to Natalie Knox Heater, Surbhi Warrior, MD MPH, and Janice Lu for their contributions to this research.
For more insights, explore the full study:https://lnkd.in/eCRKHwkn
